Oridonin suppresses gastric cancer SGC ‐7901 cell proliferation by targeting the TNF ‐alpha/androgen receptor/ TGF ‐beta signalling pathway axis

Statistics provided by GLOBOCAN list gastric cancer as the sixth most common, with a mortality ranking of third highest for the year 2020. In China, a herb called Rabdosia rubescens (Hemsl.) H.Hara, has been used by local residents for the treatment of digestive tract cancer for hundreds of years. O...

Full description

Saved in:
Bibliographic Details
Published inJournal of cellular and molecular medicine Vol. 27; no. 18; pp. 2661 - 2674
Main Authors Gao, Shiyong, Tan, Huixin, Li, Dan
Format Journal Article
LanguageEnglish
Published England John Wiley & Sons, Inc 01.09.2023
John Wiley and Sons Inc
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Statistics provided by GLOBOCAN list gastric cancer as the sixth most common, with a mortality ranking of third highest for the year 2020. In China, a herb called Rabdosia rubescens (Hemsl.) H.Hara, has been used by local residents for the treatment of digestive tract cancer for hundreds of years. Oridonin, the main ingredient of the herb, has a curative effect for gastric cancer, but the mechanism has not been previously clarified. This study mainly aimed to investigate the role of TNF‐alpha/Androgen receptor/TGF‐beta signalling pathway axis in mediating the proliferation inhibition of oridonin on gastric cancer SGC‐7901 cells. MTT assay, cell morphology observation assay and fluorescence assay were adopted to study the efficacy of oridonin on cell proliferation. The network pharmacology was used to predict the pathway axis regulated by oridonin. Western blot assay was adopted to verify the TNF‐α/Androgen receptor/TGF‐β signalling pathway axis regulation on gastric cancer by oridonin. The results showed Oridonin could inhibit the proliferation of gastric cancer cells, change cell morphology and cause cell nuclear fragmentation. A total of 11signaling pathways were annotated by the network pharmacology, among them, Tumour necrosis factor alpha (TNF‐α) signalling pathway, androgen receptor (AR) signalling pathway and transforming growth factor (TGF‐β) signalling pathway account for the largest proportion. Oridonin can regulate the protein expression of the three signalling pathways, which is consistent with the results predicted by network pharmacology. These findings indicated that oridonin can inhibit the proliferation of gastric cancer SGC‐7901 cells by regulating the TNF‐α /AR /TGF‐β signalling pathway axis.
AbstractList Statistics provided by GLOBOCAN list gastric cancer as the sixth most common, with a mortality ranking of third highest for the year 2020. In China, a herb called Rabdosia rubescens (Hemsl.) H.Hara, has been used by local residents for the treatment of digestive tract cancer for hundreds of years. Oridonin, the main ingredient of the herb, has a curative effect for gastric cancer, but the mechanism has not been previously clarified. This study mainly aimed to investigate the role of TNF-alpha/Androgen receptor/TGF-beta signalling pathway axis in mediating the proliferation inhibition of oridonin on gastric cancer SGC-7901 cells. MTT assay, cell morphology observation assay and fluorescence assay were adopted to study the efficacy of oridonin on cell proliferation. The network pharmacology was used to predict the pathway axis regulated by oridonin. Western blot assay was adopted to verify the TNF-α/Androgen receptor/TGF-β signalling pathway axis regulation on gastric cancer by oridonin. The results showed Oridonin could inhibit the proliferation of gastric cancer cells, change cell morphology and cause cell nuclear fragmentation. A total of 11signaling pathways were annotated by the network pharmacology, among them, Tumour necrosis factor alpha (TNF-α) signalling pathway, androgen receptor (AR) signalling pathway and transforming growth factor (TGF-β) signalling pathway account for the largest proportion. Oridonin can regulate the protein expression of the three signalling pathways, which is consistent with the results predicted by network pharmacology. These findings indicated that oridonin can inhibit the proliferation of gastric cancer SGC-7901 cells by regulating the TNF-α /AR /TGF-β signalling pathway axis.Statistics provided by GLOBOCAN list gastric cancer as the sixth most common, with a mortality ranking of third highest for the year 2020. In China, a herb called Rabdosia rubescens (Hemsl.) H.Hara, has been used by local residents for the treatment of digestive tract cancer for hundreds of years. Oridonin, the main ingredient of the herb, has a curative effect for gastric cancer, but the mechanism has not been previously clarified. This study mainly aimed to investigate the role of TNF-alpha/Androgen receptor/TGF-beta signalling pathway axis in mediating the proliferation inhibition of oridonin on gastric cancer SGC-7901 cells. MTT assay, cell morphology observation assay and fluorescence assay were adopted to study the efficacy of oridonin on cell proliferation. The network pharmacology was used to predict the pathway axis regulated by oridonin. Western blot assay was adopted to verify the TNF-α/Androgen receptor/TGF-β signalling pathway axis regulation on gastric cancer by oridonin. The results showed Oridonin could inhibit the proliferation of gastric cancer cells, change cell morphology and cause cell nuclear fragmentation. A total of 11signaling pathways were annotated by the network pharmacology, among them, Tumour necrosis factor alpha (TNF-α) signalling pathway, androgen receptor (AR) signalling pathway and transforming growth factor (TGF-β) signalling pathway account for the largest proportion. Oridonin can regulate the protein expression of the three signalling pathways, which is consistent with the results predicted by network pharmacology. These findings indicated that oridonin can inhibit the proliferation of gastric cancer SGC-7901 cells by regulating the TNF-α /AR /TGF-β signalling pathway axis.
Statistics provided by GLOBOCAN list gastric cancer as the sixth most common, with a mortality ranking of third highest for the year 2020. In China, a herb called Rabdosia rubescens (Hemsl.) H.Hara, has been used by local residents for the treatment of digestive tract cancer for hundreds of years. Oridonin, the main ingredient of the herb, has a curative effect for gastric cancer, but the mechanism has not been previously clarified. This study mainly aimed to investigate the role of TNF-alpha/Androgen receptor/TGF-beta signalling pathway axis in mediating the proliferation inhibition of oridonin on gastric cancer SGC-7901 cells. MTT assay, cell morphology observation assay and fluorescence assay were adopted to study the efficacy of oridonin on cell proliferation. The network pharmacology was used to predict the pathway axis regulated by oridonin. Western blot assay was adopted to verify the TNF-α/Androgen receptor/TGF-β signalling pathway axis regulation on gastric cancer by oridonin. The results showed Oridonin could inhibit the proliferation of gastric cancer cells, change cell morphology and cause cell nuclear fragmentation. A total of 11signaling pathways were annotated by the network pharmacology, among them, Tumour necrosis factor alpha (TNF-α) signalling pathway, androgen receptor (AR) signalling pathway and transforming growth factor (TGF-β) signalling pathway account for the largest proportion. Oridonin can regulate the protein expression of the three signalling pathways, which is consistent with the results predicted by network pharmacology. These findings indicated that oridonin can inhibit the proliferation of gastric cancer SGC-7901 cells by regulating the TNF-α /AR /TGF-β signalling pathway axis.
Statistics provided by GLOBOCAN list gastric cancer as the sixth most common, with a mortality ranking of third highest for the year 2020. In China, a herb called Rabdosia rubescens (Hemsl.) H.Hara, has been used by local residents for the treatment of digestive tract cancer for hundreds of years. Oridonin, the main ingredient of the herb, has a curative effect for gastric cancer, but the mechanism has not been previously clarified. This study mainly aimed to investigate the role of TNF‐alpha/Androgen receptor/TGF‐beta signalling pathway axis in mediating the proliferation inhibition of oridonin on gastric cancer SGC‐7901 cells. MTT assay, cell morphology observation assay and fluorescence assay were adopted to study the efficacy of oridonin on cell proliferation. The network pharmacology was used to predict the pathway axis regulated by oridonin. Western blot assay was adopted to verify the TNF‐α/Androgen receptor/TGF‐β signalling pathway axis regulation on gastric cancer by oridonin. The results showed Oridonin could inhibit the proliferation of gastric cancer cells, change cell morphology and cause cell nuclear fragmentation. A total of 11signaling pathways were annotated by the network pharmacology, among them, Tumour necrosis factor alpha (TNF‐α) signalling pathway, androgen receptor (AR) signalling pathway and transforming growth factor (TGF‐β) signalling pathway account for the largest proportion. Oridonin can regulate the protein expression of the three signalling pathways, which is consistent with the results predicted by network pharmacology. These findings indicated that oridonin can inhibit the proliferation of gastric cancer SGC‐7901 cells by regulating the TNF‐α /AR /TGF‐β signalling pathway axis.
Author Gao, Shiyong
Li, Dan
Tan, Huixin
AuthorAffiliation 3 Heilongjiang Provincial Key Laboratory of Tumor Prevention and Antitumor Drugs Harbin China
2 Department of Pharmacy Fourth Affiliated Hospital of Harbin Medicine University Harbin China
1 Drug Engineering and Technology Research Center Harbin University of Commerce Harbin China
AuthorAffiliation_xml – name: 1 Drug Engineering and Technology Research Center Harbin University of Commerce Harbin China
– name: 2 Department of Pharmacy Fourth Affiliated Hospital of Harbin Medicine University Harbin China
– name: 3 Heilongjiang Provincial Key Laboratory of Tumor Prevention and Antitumor Drugs Harbin China
Author_xml – sequence: 1
  givenname: Shiyong
  orcidid: 0000-0002-8499-9485
  surname: Gao
  fullname: Gao, Shiyong
  organization: Drug Engineering and Technology Research Center Harbin University of Commerce Harbin China, Heilongjiang Provincial Key Laboratory of Tumor Prevention and Antitumor Drugs Harbin China
– sequence: 2
  givenname: Huixin
  surname: Tan
  fullname: Tan, Huixin
  organization: Department of Pharmacy Fourth Affiliated Hospital of Harbin Medicine University Harbin China
– sequence: 3
  givenname: Dan
  surname: Li
  fullname: Li, Dan
  organization: Drug Engineering and Technology Research Center Harbin University of Commerce Harbin China, Heilongjiang Provincial Key Laboratory of Tumor Prevention and Antitumor Drugs Harbin China
BackLink https://www.ncbi.nlm.nih.gov/pubmed/37431884$$D View this record in MEDLINE/PubMed
BookMark eNptks9u1DAQxiNURP_AhQdAlrggpO3GsRM7J1St6IJU0QPL2XLsSdarxA62A-yNR-DEA_IkONstggpfxtL85pvPnjnPTqyzkGXPcX6J01nu1DBcYsYpfpSd4ZIXC1oTenK8Y074aXYewi7PSYVJ_SQ7JYwSzDk9y37eeqOdNRaFaRw9hAABdTJEbxRS0irw6ON6hX59_8HqHCMFfY9G73rTgpfROIuaPYrSdxCN7VDcAtp8uJ552Y9buZRWe9eBRR4UjNH5JdqsD_kGokTBdFb2_Vw6yrj9KvdIfjPhafa4lX2AZ8d4kX26frtZvVvc3K7fr65uFormLC4Aawpl22gmC6KZVqTlALIkUDYVFBo0aZSuFMNclzoFUuRaU8YKxijWNbnI3tzpjlMzgFZgo5e9GL0ZpN8LJ434N2PNVnTui8A5rWlRk6Tw6qjg3ecJQhSDCfMvSQtuCqLgJaUkL_Hc7OUDdOcmn54_U1WyVnFaJOrF35b-eLmfWQLyO0B5F4KHVigTD6NIDk2frIl5LcS8FuKwFqnk9YOSe9X_wL8BZHq-Uw
CitedBy_id crossref_primary_10_1016_j_jep_2024_119119
crossref_primary_10_1080_15384047_2024_2322206
crossref_primary_10_1016_j_intimp_2024_113935
crossref_primary_10_3389_fphar_2024_1476739
crossref_primary_10_1007_s12672_024_01281_w
crossref_primary_10_1016_j_jep_2024_118586
crossref_primary_10_1007_s12672_024_01476_1
crossref_primary_10_1016_j_ejphar_2024_176656
crossref_primary_10_1007_s10811_023_03138_1
crossref_primary_10_1016_j_ymeth_2024_07_012
crossref_primary_10_3892_ol_2024_14596
crossref_primary_10_3892_ijmm_2024_5456
crossref_primary_10_2174_0118756298310340240514060824
crossref_primary_10_1016_j_prp_2024_155688
crossref_primary_10_1016_j_ijbiomac_2024_137090
crossref_primary_10_1016_j_intimp_2024_111861
crossref_primary_10_1016_j_intimp_2025_114119
crossref_primary_10_1016_j_heliyon_2024_e34297
crossref_primary_10_1016_j_phymed_2025_156436
crossref_primary_10_3892_etm_2024_12777
crossref_primary_10_1007_s11655_024_4116_7
crossref_primary_10_1016_j_jep_2023_117020
crossref_primary_10_1177_1934578X241309226
crossref_primary_10_1007_s12013_024_01294_w
crossref_primary_10_2147_IJGM_S471370
crossref_primary_10_1002_fsn3_3986
crossref_primary_10_3892_ol_2024_14822
crossref_primary_10_1167_iovs_66_2_56
crossref_primary_10_1016_j_heliyon_2024_e34215
crossref_primary_10_20517_cdr_2024_101
crossref_primary_10_3892_mmr_2024_13282
crossref_primary_10_1016_j_jep_2024_117912
crossref_primary_10_1016_j_intimp_2024_112303
crossref_primary_10_1016_j_jep_2024_118001
crossref_primary_10_1111_jcmm_70032
crossref_primary_10_1016_j_ijbiomac_2024_136472
crossref_primary_10_2147_IJGM_S476647
crossref_primary_10_3389_fphar_2024_1522787
crossref_primary_10_1007_s00210_024_03238_w
crossref_primary_10_2217_fon_2023_0872
crossref_primary_10_3892_or_2024_8813
crossref_primary_10_1016_j_jprot_2024_105298
crossref_primary_10_3390_biomedicines13020359
crossref_primary_10_1016_j_fitote_2024_106347
crossref_primary_10_1016_j_intimp_2024_113827
crossref_primary_10_1016_j_fitote_2024_106189
crossref_primary_10_1016_j_jep_2024_118512
crossref_primary_10_1080_15321819_2024_2360083
crossref_primary_10_1016_j_jep_2024_119200
crossref_primary_10_3892_or_2024_8808
crossref_primary_10_1016_j_intimp_2024_112296
crossref_primary_10_1016_j_intimp_2024_113462
crossref_primary_10_1007_s00210_024_02980_5
crossref_primary_10_1007_s00210_024_03652_0
Cites_doi 10.1016/j.canlet.2017.10.019
10.6023/cjocx201607022
10.1038/onc.2015.133
10.4049/jimmunol.174.10.6169
10.1080/21655979.2021.2016086
10.21037/atm-21-2630
10.1155/2021/5023536
10.1016/j.omtn.2021.01.028
10.7150/jca.55929
10.1016/j.biopha.2021.111830
10.1200/JCO.21.00468
10.1172/JCI0215970
10.1186/s41065-021-00213-w
10.1016/j.intimp.2007.10.020
10.1111/jcmm.15106
10.1158/0008-5472.CAN-13-0023
10.1007/s12672-018-0336-7
10.3390/molecules25020358
10.3892/ol.2017.5751
10.1007/s00403-009-0994-y
10.3389/fphar.2019.00123
10.1002/cam4.2393
10.1016/j.ccr.2014.03.010
10.1016/j.biopha.2018.02.011
10.1002/path.5257
10.1038/nchembio.118
10.1007/s00401-002-0661-2
10.1111/eos.12387
10.3390/ijms221810030
10.3389/fbioe.2021.600579
10.1016/S0002-9440(10)62256-0
10.1080/21655979.2021.1955177
10.1186/s13058-021-01478-9
10.1021/jm401248x
10.3109/02652040903079526
10.1002/jcb.27654
10.1016/j.ijpharm.2013.03.019
10.1248/bpb.b19-00839
10.1038/nbt1007-1110
10.3390/ijms19082378
10.1039/C5NP00005J
10.1088/0957-4484/17/23/018
10.7314/APJCP.2014.15.15.6437
10.1016/j.bbadis.2021.166290
10.1016/j.biopha.2019.109667
10.1053/j.gastro.2021.04.064
10.18632/oncotarget.21880
10.1158/1541-7786.MCR-18-0558
10.5114/aoms.2018.77068
10.3892/etm.2010.145
10.1016/j.cyto.2009.08.002
10.1016/j.cellsig.2007.12.003
10.1016/j.jsps.2017.04.037
10.1016/j.cyto.2020.155066
10.1007/s10585-014-9679-9
10.1155/2021/4340950
10.1080/10837450.2021.1982966
10.3390/md14090166
10.2147/OTT.S262022
10.1007/s10517-021-05324-y
10.1097/CAD.0000000000000797
10.3892/ol.2017.6421
10.3390/ijms22147748
10.3390/ijms21197186
10.1073/pnas.080583397
10.1001/jamaoncol.2016.4975
10.1093/abbs/gmz071
10.1038/s41419-021-04177-7
10.3892/ijo.2016.3479
10.3109/10428194.2015.1061127
10.1016/j.bbrc.2019.04.011
10.1016/j.canlet.2013.11.019
10.1111/j.1755-148X.2008.00450.x
10.1016/j.jhep.2021.06.016
10.1200/JCO.21.01983
ContentType Journal Article
Copyright 2023 The Authors. Journal of Cellular and Molecular Medicine published by Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd.
2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
2023 The Authors. published by Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd.
Copyright_xml – notice: 2023 The Authors. Journal of Cellular and Molecular Medicine published by Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd.
– notice: 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: 2023 The Authors. published by Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd.
DBID AAYXX
CITATION
NPM
3V.
7QP
7TK
7X7
7XB
88E
88I
8AO
8FD
8FE
8FH
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BBNVY
BENPR
BHPHI
CCPQU
DWQXO
FR3
FYUFA
GHDGH
GNUQQ
HCIFZ
K9.
LK8
M0S
M1P
M2P
M7P
P64
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQGLB
PQQKQ
PQUKI
PRINS
Q9U
RC3
7X8
5PM
DOI 10.1111/jcmm.17841
DatabaseName CrossRef
PubMed
ProQuest Central (Corporate)
Calcium & Calcified Tissue Abstracts
Neurosciences Abstracts
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Science Database (Alumni Edition)
ProQuest Pharma Collection
Technology Research Database
ProQuest SciTech Collection
ProQuest Natural Science Journals
ProQuest Hospital Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
Biological Science Collection
ProQuest Central
Natural Science Collection
ProQuest One Community College
ProQuest Central
Engineering Research Database
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
SciTech Premium Collection
ProQuest Health & Medical Complete (Alumni)
Biological Sciences
ProQuest Health & Medical Collection
Proquest Medical Database
Science Database
Biological Science Database
Biotechnology and BioEngineering Abstracts
ProQuest Central Premium
ProQuest One Academic
Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Applied & Life Sciences
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
ProQuest Central Basic
Genetics Abstracts
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
PubMed
Publicly Available Content Database
ProQuest Central Student
Technology Research Database
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Natural Science Collection
ProQuest Pharma Collection
ProQuest Central China
ProQuest Central
ProQuest One Applied & Life Sciences
ProQuest Health & Medical Research Collection
Genetics Abstracts
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
Natural Science Collection
ProQuest Central Korea
Health & Medical Research Collection
Biological Science Collection
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest Science Journals (Alumni Edition)
ProQuest Biological Science Collection
ProQuest Central Basic
ProQuest Science Journals
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
Biological Science Database
ProQuest SciTech Collection
Neurosciences Abstracts
ProQuest Hospital Collection (Alumni)
Biotechnology and BioEngineering Abstracts
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
Engineering Research Database
ProQuest One Academic
Calcium & Calcified Tissue Abstracts
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
Publicly Available Content Database
CrossRef

PubMed
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Biology
DocumentTitleAlternate Gao et al
EISSN 1582-4934
EndPage 2674
ExternalDocumentID PMC10494293
37431884
10_1111_jcmm_17841
Genre Journal Article
GeographicLocations China
GeographicLocations_xml – name: China
GrantInformation_xml – fundername: Outstanding Young Talents Project of the Central Government's Fund for Local Universities' Reform and Development
  grantid: 2020YQ12
– fundername: 2021 Harbin University of Commerce Teacher "Innovation" Project
  grantid: LH2021H002;
– fundername: General Project of Education Department of Heilongjiang Province
  grantid: 12541571
– fundername: Natural Science Foundation in Heilongjiang Province
  grantid: LH2021H002
– fundername: Science and Technology Project of Heilongjiang Provincial Health and Family Planning Commission
  grantid: 2017-132
– fundername: Outstanding Young Talents Project of the Central Government's Fund for Local Universities’ Reform and Development
  grantid: 2020YQ12
– fundername: Science and Technology Project of Heilongjiang Provincial Health and Family Planning Commission
  grantid: 2017‐132
GroupedDBID ---
0R~
1OC
24P
29K
31~
36B
4.4
53G
5GY
5VS
7X7
8-0
8-1
88E
88I
8AO
8FE
8FH
8FI
8FJ
8R4
8R5
AAHHS
AAYXX
AAZKR
ABJNI
ABUWG
ACCFJ
ACCMX
ACGFS
ACGOD
ACXQS
ADBBV
ADKYN
ADPDF
ADRAZ
ADZMN
ADZOD
AEEZP
AENEX
AEQDE
AFBPY
AFKRA
AFZJQ
AHMBA
AIWBW
AJBDE
ALAGY
ALIPV
ALMA_UNASSIGNED_HOLDINGS
ALUQN
AOIJS
AVUZU
AZQEC
BAWUL
BBNVY
BCNDV
BENPR
BHPHI
BPHCQ
BVXVI
CAG
CCPQU
CITATION
COF
CS3
D-9
D-I
DIK
DU5
DWQXO
E3Z
EBD
EBS
EJD
EMB
EMOBN
F5P
FYUFA
GNUQQ
GODZA
GROUPED_DOAJ
HCIFZ
HMCUK
HYE
HZ~
IAO
IHR
ITC
KQ8
LH4
LK8
LW6
M1P
M2P
M48
M7P
O9-
OIG
OK1
OVD
OVEED
PHGZM
PHGZT
PIMPY
PQQKQ
PROAC
PSQYO
Q2X
RNS
ROL
RPM
SV3
TEORI
UKHRP
NPM
WIN
3V.
7QP
7TK
7XB
8FD
8FK
AAMMB
AEFGJ
AGXDD
AIDQK
AIDYY
FR3
K9.
P64
PJZUB
PKEHL
PPXIY
PQEST
PQGLB
PQUKI
PRINS
Q9U
RC3
7X8
5PM
ID FETCH-LOGICAL-c407t-e1d4e5fbd7a23d7dc3f8eea53e5b6e2ded3bcd6c718d5dc71320dd47727741d93
IEDL.DBID M48
ISSN 1582-1838
1582-4934
IngestDate Thu Aug 21 18:36:27 EDT 2025
Tue Aug 05 10:26:46 EDT 2025
Wed Aug 13 06:13:02 EDT 2025
Wed Feb 19 02:22:19 EST 2025
Thu Apr 24 22:58:16 EDT 2025
Tue Jul 01 01:35:22 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 18
Keywords oridonin
AR signalling pathway
TGF-β signalling pathway
gastric cancer
TNF-α signalling pathway
Language English
License 2023 The Authors. Journal of Cellular and Molecular Medicine published by Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd.
This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c407t-e1d4e5fbd7a23d7dc3f8eea53e5b6e2ded3bcd6c718d5dc71320dd47727741d93
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
Shiyong Gao and Huixin Tan should be considered joint first author.
Shiyong Gao and Huixin Tan contributed equally.
ORCID 0000-0002-8499-9485
OpenAccessLink http://journals.scholarsportal.info/openUrl.xqy?doi=10.1111/jcmm.17841
PMID 37431884
PQID 2863206842
PQPubID 2034150
PageCount 14
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_10494293
proquest_miscellaneous_2854430519
proquest_journals_2863206842
pubmed_primary_37431884
crossref_citationtrail_10_1111_jcmm_17841
crossref_primary_10_1111_jcmm_17841
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2023-09-01
PublicationDateYYYYMMDD 2023-09-01
PublicationDate_xml – month: 09
  year: 2023
  text: 2023-09-01
  day: 01
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
– name: Chichester
– name: Hoboken
PublicationTitle Journal of cellular and molecular medicine
PublicationTitleAlternate J Cell Mol Med
PublicationYear 2023
Publisher John Wiley & Sons, Inc
John Wiley and Sons Inc
Publisher_xml – name: John Wiley & Sons, Inc
– name: John Wiley and Sons Inc
References e_1_2_11_70_1
e_1_2_11_72_1
Li S (e_1_2_11_18_1) 2018; 16
e_1_2_11_32_1
e_1_2_11_55_1
Sikic D (e_1_2_11_59_1) 2021; 11
e_1_2_11_78_1
e_1_2_11_30_1
e_1_2_11_57_1
e_1_2_11_36_1
e_1_2_11_51_1
e_1_2_11_13_1
e_1_2_11_34_1
e_1_2_11_53_1
e_1_2_11_76_1
e_1_2_11_11_1
e_1_2_11_29_1
e_1_2_11_6_1
e_1_2_11_27_1
e_1_2_11_4_1
e_1_2_11_48_1
Bialek J (e_1_2_11_64_1) 2021; 11
Yang D (e_1_2_11_66_1) 2001; 61
Takahashi K (e_1_2_11_74_1) 2021; 112
e_1_2_11_60_1
e_1_2_11_81_1
e_1_2_11_20_1
e_1_2_11_45_1
e_1_2_11_47_1
e_1_2_11_68_1
e_1_2_11_24_1
e_1_2_11_41_1
e_1_2_11_62_1
e_1_2_11_8_1
e_1_2_11_22_1
e_1_2_11_43_1
e_1_2_11_17_1
e_1_2_11_15_1
e_1_2_11_38_1
e_1_2_11_19_1
e_1_2_11_50_1
e_1_2_11_71_1
Commission NP (e_1_2_11_2_1) 2020
e_1_2_11_10_1
e_1_2_11_31_1
e_1_2_11_56_1
e_1_2_11_77_1
e_1_2_11_58_1
e_1_2_11_79_1
e_1_2_11_14_1
e_1_2_11_35_1
e_1_2_11_52_1
e_1_2_11_73_1
e_1_2_11_12_1
e_1_2_11_33_1
e_1_2_11_54_1
e_1_2_11_75_1
e_1_2_11_7_1
e_1_2_11_28_1
e_1_2_11_5_1
e_1_2_11_26_1
e_1_2_11_3_1
e_1_2_11_49_1
e_1_2_11_82_1
e_1_2_11_61_1
e_1_2_11_80_1
e_1_2_11_21_1
e_1_2_11_44_1
e_1_2_11_67_1
e_1_2_11_46_1
e_1_2_11_69_1
e_1_2_11_25_1
e_1_2_11_40_1
e_1_2_11_63_1
e_1_2_11_9_1
e_1_2_11_23_1
e_1_2_11_42_1
e_1_2_11_65_1
e_1_2_11_16_1
e_1_2_11_37_1
e_1_2_11_39_1
References_xml – volume-title: Pharmacopoeia of People's Republic of China (2020 Edition)
  year: 2020
  ident: e_1_2_11_2_1
– ident: e_1_2_11_71_1
  doi: 10.1016/j.canlet.2017.10.019
– ident: e_1_2_11_8_1
  doi: 10.6023/cjocx201607022
– ident: e_1_2_11_70_1
  doi: 10.1038/onc.2015.133
– ident: e_1_2_11_80_1
  doi: 10.4049/jimmunol.174.10.6169
– ident: e_1_2_11_50_1
  doi: 10.1080/21655979.2021.2016086
– ident: e_1_2_11_16_1
  doi: 10.21037/atm-21-2630
– ident: e_1_2_11_29_1
  doi: 10.1155/2021/5023536
– ident: e_1_2_11_58_1
  doi: 10.1016/j.omtn.2021.01.028
– ident: e_1_2_11_4_1
  doi: 10.7150/jca.55929
– ident: e_1_2_11_17_1
  doi: 10.1016/j.biopha.2021.111830
– ident: e_1_2_11_62_1
  doi: 10.1200/JCO.21.00468
– ident: e_1_2_11_77_1
  doi: 10.1172/JCI0215970
– ident: e_1_2_11_72_1
  doi: 10.1186/s41065-021-00213-w
– ident: e_1_2_11_82_1
  doi: 10.1016/j.intimp.2007.10.020
– volume: 61
  start-page: 5857
  issue: 15
  year: 2001
  ident: e_1_2_11_66_1
  article-title: Murine six‐transmembrane epithelial antigen of the prostate, prostate stem cell antigen, and prostate‐specific membrane antigen: prostate‐specific cell‐surface antigens highly expressed in prostate cancer of transgenic adenocarcinoma mouse prostate mice
  publication-title: Cancer Res
– ident: e_1_2_11_19_1
  doi: 10.1111/jcmm.15106
– ident: e_1_2_11_68_1
  doi: 10.1158/0008-5472.CAN-13-0023
– ident: e_1_2_11_57_1
  doi: 10.1007/s12672-018-0336-7
– ident: e_1_2_11_51_1
  doi: 10.3390/molecules25020358
– ident: e_1_2_11_21_1
  doi: 10.3892/ol.2017.5751
– ident: e_1_2_11_44_1
  doi: 10.1007/s00403-009-0994-y
– ident: e_1_2_11_35_1
  doi: 10.3389/fphar.2019.00123
– ident: e_1_2_11_38_1
  doi: 10.1002/cam4.2393
– ident: e_1_2_11_69_1
  doi: 10.1016/j.ccr.2014.03.010
– ident: e_1_2_11_25_1
  doi: 10.1016/j.biopha.2018.02.011
– ident: e_1_2_11_56_1
  doi: 10.1002/path.5257
– ident: e_1_2_11_34_1
  doi: 10.1038/nchembio.118
– ident: e_1_2_11_49_1
  doi: 10.1007/s00401-002-0661-2
– ident: e_1_2_11_24_1
  doi: 10.1111/eos.12387
– ident: e_1_2_11_60_1
  doi: 10.3390/ijms221810030
– ident: e_1_2_11_14_1
  doi: 10.3389/fbioe.2021.600579
– ident: e_1_2_11_46_1
  doi: 10.1016/S0002-9440(10)62256-0
– ident: e_1_2_11_76_1
  doi: 10.1080/21655979.2021.1955177
– ident: e_1_2_11_52_1
  doi: 10.1186/s13058-021-01478-9
– ident: e_1_2_11_5_1
  doi: 10.1021/jm401248x
– ident: e_1_2_11_6_1
  doi: 10.3109/02652040903079526
– ident: e_1_2_11_23_1
  doi: 10.1002/jcb.27654
– ident: e_1_2_11_9_1
  doi: 10.1016/j.ijpharm.2013.03.019
– ident: e_1_2_11_30_1
  doi: 10.1248/bpb.b19-00839
– ident: e_1_2_11_33_1
  doi: 10.1038/nbt1007-1110
– ident: e_1_2_11_39_1
  doi: 10.3390/ijms19082378
– ident: e_1_2_11_42_1
  doi: 10.1039/C5NP00005J
– ident: e_1_2_11_10_1
  doi: 10.1088/0957-4484/17/23/018
– ident: e_1_2_11_31_1
  doi: 10.7314/APJCP.2014.15.15.6437
– volume: 112
  start-page: 418
  year: 2021
  ident: e_1_2_11_74_1
  article-title: TGF‐beta‐induced cell cycle arrest is associated with increased migration and metastasis of oral squamous carcinoma cells
  publication-title: Cancer Sci
– ident: e_1_2_11_67_1
  doi: 10.1016/j.bbadis.2021.166290
– ident: e_1_2_11_55_1
  doi: 10.1016/j.biopha.2019.109667
– ident: e_1_2_11_79_1
  doi: 10.1053/j.gastro.2021.04.064
– volume: 11
  start-page: 731
  issue: 8
  year: 2021
  ident: e_1_2_11_64_1
  article-title: Differential expression of the androgen receptor, splice variants and relaxin 2 in renal cancer
  publication-title: Life (Basel)
– ident: e_1_2_11_27_1
  doi: 10.18632/oncotarget.21880
– ident: e_1_2_11_73_1
  doi: 10.1158/1541-7786.MCR-18-0558
– ident: e_1_2_11_22_1
  doi: 10.5114/aoms.2018.77068
– ident: e_1_2_11_37_1
  doi: 10.3892/etm.2010.145
– ident: e_1_2_11_45_1
  doi: 10.1016/j.cyto.2009.08.002
– ident: e_1_2_11_48_1
  doi: 10.1016/j.cellsig.2007.12.003
– ident: e_1_2_11_13_1
  doi: 10.1016/j.jsps.2017.04.037
– ident: e_1_2_11_43_1
  doi: 10.1016/j.cyto.2020.155066
– ident: e_1_2_11_65_1
  doi: 10.1007/s10585-014-9679-9
– ident: e_1_2_11_26_1
  doi: 10.1155/2021/4340950
– ident: e_1_2_11_7_1
  doi: 10.1080/10837450.2021.1982966
– ident: e_1_2_11_36_1
  doi: 10.3390/md14090166
– ident: e_1_2_11_3_1
  doi: 10.2147/OTT.S262022
– ident: e_1_2_11_11_1
  doi: 10.1007/s10517-021-05324-y
– ident: e_1_2_11_20_1
  doi: 10.1097/CAD.0000000000000797
– ident: e_1_2_11_28_1
  doi: 10.3892/ol.2017.6421
– ident: e_1_2_11_54_1
  doi: 10.3390/ijms22147748
– ident: e_1_2_11_41_1
  doi: 10.3390/ijms21197186
– volume: 11
  start-page: 642
  issue: 7
  year: 2021
  ident: e_1_2_11_59_1
  article-title: High androgen receptor mRNA expression is associated with improved outcome in patients with high‐risk non‐muscle‐invasive bladder cancer
  publication-title: Life (Basel)
– ident: e_1_2_11_81_1
  doi: 10.1073/pnas.080583397
– volume: 16
  start-page: 4859
  issue: 6
  year: 2018
  ident: e_1_2_11_18_1
  article-title: Oridonin enhances the radiosensitivity of lung cancer cells by upregulating Bax and downregulating Bcl‐2
  publication-title: Exp Ther Med
– ident: e_1_2_11_53_1
  doi: 10.1001/jamaoncol.2016.4975
– ident: e_1_2_11_15_1
  doi: 10.1093/abbs/gmz071
– ident: e_1_2_11_75_1
  doi: 10.1038/s41419-021-04177-7
– ident: e_1_2_11_32_1
  doi: 10.3892/ijo.2016.3479
– ident: e_1_2_11_40_1
  doi: 10.3109/10428194.2015.1061127
– ident: e_1_2_11_12_1
  doi: 10.1016/j.bbrc.2019.04.011
– ident: e_1_2_11_47_1
  doi: 10.1016/j.canlet.2013.11.019
– ident: e_1_2_11_78_1
  doi: 10.1111/j.1755-148X.2008.00450.x
– ident: e_1_2_11_63_1
  doi: 10.1016/j.jhep.2021.06.016
– ident: e_1_2_11_61_1
  doi: 10.1200/JCO.21.01983
SSID ssj0036139
Score 2.6010568
Snippet Statistics provided by GLOBOCAN list gastric cancer as the sixth most common, with a mortality ranking of third highest for the year 2020. In China, a herb...
SourceID pubmedcentral
proquest
pubmed
crossref
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 2661
SubjectTerms Androgen receptors
Antibodies
Apoptosis
Cell morphology
Cell proliferation
Cells
Cytology
DNA fragmentation
Gastric cancer
Gastrointestinal tract
Herbs
Interdisciplinary subjects
Medical research
Morphology
Original
Pharmacology
Proteins
R&D
Research & development
Research methodology
Signal transduction
Statistical analysis
Transforming growth factor-b
Tumor necrosis factor-α
SummonAdditionalLinks – databaseName: Health & Medical Collection
  dbid: 7X7
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3PT9swFLZGp0lcpv0CuhVktF12ME3i_DxNE1pBO8BhReotcvxsqETT0LTa-j_sj957ThpWQJxysKVEfrbf9-wv38fYFy8NibPoCQiKWISk3pr5WgvrhwkWRFp71ql9XsTnV-HPSTRpD9zqlla52RPdRg1zTWfkwyCNZeDRrdG36k6QaxTdrrYWGjvsJUmXEaUrmXQFl8RUlbWSpI69o2ezE58u2raT0CNk-ZAg-V_GGb1hr1uoyL83sX3LXpjyHXvVmEeu37O_l4sp0GEqr1eVo7Oaml8r8uHQXFMwF_zX2alIMBdzOp_nFTn0WNPEnBdr3tDAMXlxhIF8fDES7tfboSIVA5xZHLdDU2FVPhyfjURhlooT30M5HW9OZsa_1ZqrP9P6A7sa_RifnovWW0FoLOGWwvgQmsgWkKhAQgJa2tQYFUkTFbEJwIAsNMQaUxdEgA8cfIAQsTjiRR8yucd65bw0B4wH0vhRohEnWEB4l2UWbBYq6yVW-kqFffZ1M9i5boXHyf_iNu8KEAxM7gLTZ5-7vlUjt_Fkr8EmZnm75Or8foL02XHXjIuFRliVZr6iPiT3R6i1z_abEHevkYSl0hQ_N90KfteBhLi3W8rpjRPk9klkB3HTx-e_6xPbJbP6hqE2YL3lYmUOEdIsiyM3b_8BdMf7Ow
  priority: 102
  providerName: ProQuest
Title Oridonin suppresses gastric cancer SGC ‐7901 cell proliferation by targeting the TNF ‐alpha/androgen receptor/ TGF ‐beta signalling pathway axis
URI https://www.ncbi.nlm.nih.gov/pubmed/37431884
https://www.proquest.com/docview/2863206842
https://www.proquest.com/docview/2854430519
https://pubmed.ncbi.nlm.nih.gov/PMC10494293
Volume 27
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3JbtRAEC1lESgXFNY4hFEjuHBwYrvb2wFFIcokQmJAMEYjLla7FzJS4kxmEZkbn4D4RL6EKm9iICdOPnRZtrqqXa-6y-8BvPQSQT2LnquDInIFsbemvlKu9UWMBZFSnq3YPgfRWSbejsLRGrT6nc0Ezm4t7UhPKpte7N9cLw9xwb_uunLU5eW-Twdo67CJGSmmBfpOdKcJHFNWWvGmIprEEE4amtLVe7fgLqd0miRiNUf9Azz_7p_8IyH1t-FegyTZUe36-7Bmygdwp9aWXD6En--nY017rWy2mFTdrmbGvkqS6VBMka-n7NPp8a_vP2JM1ow28NmEJHysqYOCFUtW94ljdmOIE9lw0Efz6u_cA0lEBxh8DL-YZoKF-8HwlEYLM5eMmkJkRfbNSPH4m1wyeTOePYKsfzI8PnMbAQZXYZ03d42vhQltoWMZcB1rxW1ijAy5CYvIBNpoXigdKcxvOtR44YGntUDAjqDS1yl_DBvlVWl2gAXc-GGsEExYjRgwTa22qZDWiy33pRQOvGqnPFcNOzmJZFzkXZWCnsorTznworOd1Jwct1rttZ7L27DKgyTCd6SzRweed8O4omiWZWmuFmRDnIAEbR14Uju6e0wbIQ4kKyHQGRBb9-pIOT6vWLt9YuJBcLX7_7c-hS1Su69b3PZgYz5dmGeIieZFD9bjUdyDzaPP2ZcMr29OBh8-9qodhl61GH4Ds4kXZA
linkProvider Scholars Portal
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9NAEB5VqRBcEG8CBRYBBw5LbK-fB4SgNE1pCQhSqTd3vY82EnVM4qjkP_Bb-I3M-AUBxK0nH3alXe3Mznzjmf0G4KkT-1Sz6HDtZSH3ib01cZXi1vUjDIiUcmzF9jkOR4f-u6PgaAN-tG9hqKyytYmVodYzRf_IB14cCs-hrNGr4iunrlGUXW1baNRqsW9W5xiyLV7uvUX5PvO84c5ke8SbrgJcYfBScuNq3wQ205H0hI60EjY2RgbCBFloPG20yJQOFRptHWj84LJa-4hCESm5msiX0ORv-gJDmR5svtkZf_zU2n6BzjFpSFCreiF1dvbCpdTeutv7C8v-WZL5m48bXoOrDThlr2ttug4bJr8Bl-p2laub8P3DfKrp9y1bLIuqgNYs2Imkzh-KKVKfOfu8u80j9P6MMgKsoJ5A1tRaxrIVqwvP0V0yBJ5sMh7y6rHvQBJvAuoyQwNsinI2H0x2hzwzpWRUYSIr5nBG7ZPP5YrJb9PFLTi8kHO_Db18lpu7wDxh3CBSiEysRkCZJFbbxJfWiaxwpfT78Lw97FQ1VOfUceNL2oU8KJi0EkwfnnRzi5rg45-ztlqZpc0lX6S_VLIPj7thvJ50wjI3syXNIYJBwsl9uFOLuFtGEHqLY9xuvCb8bgJRf6-P5NPTigLcJVofRGr3_r-vR3B5NHl_kB7sjffvwxUPAVpdH7cFvXK-NA8QUJXZw0aLGRxf9MX5CftcO5k
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3LbtQwFLWqIhAbxJuBAkbAgoWZOM5zgRBqSVuKBiSm0uyC4wcdqc2ESUZl_oEv4uu413nAAGLXVRaxFMv34XPj43MJeeYlAXIWPab9ImIBqremXClmeRBDQaSUZ53a5yQ6OA7ezcLZFvnR34VBWmWfE12i1guF_8jHfhIJ38NTo7HtaBEf97LX1VeGHaTwpLVvp9G6yJFZn0P5Vr863ANbP_f97O1094B1HQaYgkKmYYbrwIS20LH0hY61EjYxRobChEVkfG20KJSOFCRwHWp4wBS0DgCRAmriGoWYIP1fikXIMcbi2VDsCdgm004O1TGH1NnZS46HfJsb4F-o9k9y5m-7XXadXOtgKn3T-tUNsmXKm-Ry27hyfYt8_7Cca_yRS-tV5ai0pqZfJPYAUVShIy3pp_1dFgMOoHg2QCvsDmRN62-0WNOWgg4bJwUISqeTjLlrv2OJCgrg1RRSsamaxXI83c9YYRpJkWsinYY4xUbK53JN5bd5fZscX8iq3yHb5aI09wj1heFhrACjWA3QMk2ttmkgrRdbwaUMRuRFv9i56kTPsffGaT4UP2CY3BlmRJ4OY6tW6uOfo3Z6m-VduNf5L-cckSfDawhUXGFZmsUKx6DUICLmEbnbmnj4jEAclyQw3WTD-MMAFAHffFPOT5wYOEeBH8Bs9_8_r8fkCoRL_v5wcvSAXPUBqbVEuR2y3SxX5iEgq6Z45FyYks8XHTM_Acp5Pmk
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Oridonin+suppresses+gastric+cancer+SGC%E2%80%907901+cell+proliferation+by+targeting+the+TNF%E2%80%90alpha%2Fandrogen+receptor%2FTGF%E2%80%90beta+signalling+pathway+axis&rft.jtitle=Journal+of+cellular+and+molecular+medicine&rft.au=Gao%2C+Shiyong&rft.au=Tan%2C+Huixin&rft.au=Li%2C+Dan&rft.date=2023-09-01&rft.pub=John+Wiley+and+Sons+Inc&rft.issn=1582-1838&rft.eissn=1582-4934&rft.volume=27&rft.issue=18&rft.spage=2661&rft.epage=2674&rft_id=info:doi/10.1111%2Fjcmm.17841&rft_id=info%3Apmid%2F37431884&rft.externalDocID=PMC10494293
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1582-1838&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1582-1838&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1582-1838&client=summon